New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

(2020) Zhiyi Lan et al.   Lancet Respiratory Medicine

What is behind programmatic treatment outcome definitions for tuberculosis?

(2020) Zaza Avaliani et al.   EUROPEAN RESPIRATORY JOURNAL

World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update

(2020) Fuad Mirzayev et al.   EUROPEAN RESPIRATORY JOURNAL

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

(2019) Sergey Borisov et al.   EUROPEAN RESPIRATORY JOURNAL

Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa

(2018) Olatunde Olayanju et al.   EUROPEAN RESPIRATORY JOURNAL

Evolution of programmatic definitions used in tuberculosis prevention and care

(2018) Giovanni Battista Migliori et al.   CLINICAL INFECTIOUS DISEASES

Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region

(2017) Danila V. Zimenkov et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

(2017) Keertan Dheda et al.   Lancet Respiratory Medicine

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance

(2016) Matteo Zignol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

(2012) Dennis Falzon et al.   EUROPEAN RESPIRATORY JOURNAL